Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma

Li Tzong Chen, Jaw Town Lin, John Jen Tai, Gran Hum Chen, Hong Zen Yeh, Sheng Shun Yang, Hsiu Po Wang, Sung Hsin Kuo, Bor Shyang Sheu, Chang Ming Jan, Wen Ming Wang, Tsang En Wang, Chew Wun Wu, Chi Long Chen, Ih Jen Su, Jacqueline Whang-Peng, Ann Lii Cheng

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Background: Several independent clinical studies have reported that Helicobacter pylori eradication therapy could achieve complete remission in some patients with H. pylori-positive early-stage gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Methods: To compare the long-term results of anti-H. pylori therapy in early-stage, gastric low-grade and high-grade transformed MALT lymphoma, two multicenter prospective studies of anti-H. pylori therapy for early-stage gastric lymphoma conducted in Taiwan, one for low-grade MALT lymphoma, with 34 patients enrolled from March 1996 through April 1999, and one for high-grade transformed tumors (diffuse large B-cell lymphoma with features of MALT, DLBCL[MALT] lymphoma), with 24 patients enrolled since June 1995, were directly compared. In both studies, patients generally received 2 weeks of antibiotics and had multiple sequential follow-up endoscopic examinations until complete histologic remission (CR) or disease progression; patients were monitored through January 31, 2004. CR was defined as regression of lymphoid infiltration to Wotherspoon's score of 2 or less on all pathologic sections of endoscopic biopsy specimens. All statistical tests were two-sided. Results: The H. pylori-positive rate among the 34 low-grade patients was 94% (32 of 34). All 24 selected high-grade patients were H. pylori positive. H. pylori was eradicated in 97% (30 of 31) of evaluable H. pylori-positive low-grade patients and in 92% (22 of 24) of high-grade patients, which led to CR in 80% (24 of 30, 95% confidence interval [CI] = 65% to 95%) and 64% (14 of 22, 95% CI = 42% to 86%) of patients, respectively. None of the five patients who were either initially H. pylori negative or had persistent H. pylori infection after antibiotics achieved CR. After median follow-up of more than 5 years in complete responders, tumor recurrence was observed in three (13%) low-grade patients but not in high-grade patients. Conclusions: Anti-H. pylori therapy may be considered as one of the treatment options for early-stage H. pylori-positive gastric DLBCL(MALT), and large-scale prospective studies to validate its use as first-line therapy for such tumors should be undertaken.

Original languageEnglish
Pages (from-to)1345-1353
Number of pages9
JournalJournal of the National Cancer Institute
Volume97
Issue number18
DOIs
Publication statusPublished - Sep 2005

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chen, L. T., Lin, J. T., Tai, J. J., Chen, G. H., Yeh, H. Z., Yang, S. S., Wang, H. P., Kuo, S. H., Sheu, B. S., Jan, C. M., Wang, W. M., Wang, T. E., Wu, C. W., Chen, C. L., Su, I. J., Whang-Peng, J., & Cheng, A. L. (2005). Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. Journal of the National Cancer Institute, 97(18), 1345-1353. https://doi.org/10.1093/jnci/dji277